Browse by author
Lookup NU author(s): Professor Alastair GreystokeORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2025 Elsevier B.V.Lung cancer is mostly a disease of aging with approximately half of newly diagnosed patients being 70 years or older. Treatment decisions in this population pose unique challenges because of their heterogeneity with regards to daily functioning, cognition, organ function, comorbidities and polypharmacy, their underrepresentation in clinical trials and the impact of treatment on patient-centered outcomes, particularly in frail patients. The advent of targeted therapies and immunotherapy has revolutionized the management of advanced non-small cell lung cancer (NSCLC). Molecular profiling has allowed for the identification of actionable genomic alterations and targeted therapies have become standard of care for oncogene-driven NSCLC, significantly improving prognosis and quality of life. However, the data on the efficacy and tolerability of these treatments in older patients remain sparse. This review, conducted by the International Society of Geriatric Oncology (SIOG) NSCLC task force, examines the available literature on the use of targeted therapies in patients aged 70 years or older with oncogene-driven NSCLC. The task force's expert recommendations aim to guide treatment decisions for older patients with oncogene driven NSCLC.
Author(s): Decoster L, Camidge DR, Fletcher JA, Addeo A, Greystoke A, Kantilal K, Game LB, Kanesvaran R, Gomes F
Publication type: Review
Publication status: Published
Journal: Lung Cancer
Year: 2025
Volume: 200
Print publication date: 01/02/2025
Online publication date: 13/01/2025
Acceptance date: 12/01/2025
ISSN (print): 0169-5002
ISSN (electronic): 1872-8332
Publisher: Elsevier Ireland Ltd
URL: https://doi.org/10.1016/j.lungcan.2025.108087
DOI: 10.1016/j.lungcan.2025.108087
